A study of the combination of oxaliplatin, capecitabine, and trastuzumab and chemo-radiotherapy in the adjuvant setting in operated patients with HER2+gastric or gastroesophageal junction cancer (TOXAG study).


Abali H. , Yalcin S. , Onal C., Dane F., Oksuzoglu B., Ozdemir N., ...More

Gastrointestinal Cancers Symposium, San-Francisco, Costa Rica, 18 - 20 January 2018, vol.36 identifier